Ramucirumab is a monoclonal antibody that specifically targets vascular endothelial growth factor receptor 2 (VEGFR-2), playing a crucial role in inhibiting angiogenesis, which is the formation of new blood vessels. This characteristic makes it particularly valuable in cancer therapy, as tumors often exploit angiogenesis to grow and metastasize. Ramucirumab is primarily used in the treatment of various cancers, including gastric cancer and non-small cell lung cancer, often in combination with other therapeutic agents. The drug is administered via intravenous infusion and has a relatively long half-life, allowing for less frequent dosing. Its mechanism of action involves blocking the binding of VEGF to its receptor, thereby disrupting the signaling pathways that promote tumor blood supply. Common side effects may include hypertension, fatigue, and gastrointestinal issues, reflecting its impact on vascular health. As a biologic agent, Ramucirumab is produced through recombinant DNA technology, ensuring a high degree of specificity and efficacy in targeting cancerous tissues.

Ramucirumab

947687-13-0: Ramucirumab is a monoclonal antibody that specifically targets vascular endothelial growth factor receptor 2 (VEGFR-2), playing a crucial role in inhibiting angiogenesis, which is the formation of new blood vessels. This characteristic makes it particularly valuable in cancer therapy, as tumors often exploit angiogenesis to grow and metastasize. Ramucirumab is primarily used in the treatment of various cancers, including gastric cancer and non-small cell lung cancer, often in combination with other therapeutic agents. The drug is administered via intravenous infusion and has a relatively long half-life, allowing for less frequent dosing. Its mechanism of action involves blocking the binding of VEGF to its receptor, thereby disrupting the signaling pathways that promote tumor blood supply. Common side effects may include hypertension, fatigue, and gastrointestinal issues, reflecting its impact on vascular health. As a biologic agent, Ramucirumab is produced through recombinant DNA technology, ensuring a high degree of specificity and efficacy in targeting cancerous tissues.

<p>Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.</p>

CAS 947687-13-0

Ramucirumab

Ramucirumab

Ref: TM-T9929

Ramucirumab

Ref: 3D-FR159043